-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Immune-related adverse events (irAE) related to immune checkpoint inhibitor (ICI) treatment are a new major challenge facing patients and clinicians .
Immune-related adverse events (irAE) related to immune checkpoint inhibitor (ICI) treatment are a major new challenge facing patients and clinicians.
At present, the occurrence and management of irAE when immunotherapy is used as adjuvant therapy has an unclear impact on patients' relapse-free survival (RFS) and overall survival (OS).
management
1673 patients with high-risk melanoma after surgical resection were recruited to evaluate the adjuvant treatment of Ipilimumab 3 mg/kg (ipi3) and 10 mg/kg (ipi10) vs.
The results of the study showed that the occurrence of grade 1-2 irAE was related to RFS (5 years RFS with vs without AE: 52%[95%CI 47%-56%] vs 41%[31%-50%], p=0.
The occurrence of grade 1-2 irAE is related to RFS and also has a tendency to improve OS
RFS (Picture A) and OS (Picture B) of patients with irAE
RFS (Picture A) and OS (Picture B) of patients with irAEAmong the specific irAEs, the correlation between grade 1-2 rash and RFS and OS was the most significant (p 0.
Among specific irAEs, grade 1-2 skin rashes have the most significant correlation with RFS and OS
RFS (panel A) and OS (panel B) in three groups of patients with grade 1-2 irAE, grade 3-4 irAE and no irAE
RFS (panel A) and OS (panel B) in three groups of patients with grade 1-2 irAE, grade 3-4 irAE and no irAEOverall, compared with no irAE, patients with grade 1-2 irAE have the best prognosis for RFS and OS, while patients with grade 3-4 irAE have less benefit from RFS (there is no difference between OS and no irAE) .
Compared with no irAE, patients with grade 1-2 irAE have the best prognosis for RFS and OS, while patients with grade 3-4 irAE have less benefit from RFS (there is no difference between OS and no irAE)
Exposure to steroids and immunosuppressants of patients in different groups
Exposure to steroids and immunosuppressants of patients in different groupsIn summary, skin rash and endocrine irAE are independent prognostic factors of RFS and OS in patients treated with adjuvant ipilimumab .
Rash and endocrine irAEs are independent prognostic factors of RFS and OS in patients receiving adjuvant ipilimumab.
Original source:
Tarhini Ahmad A,Kang Ni,Lee Sandra J et al.
org/10.
1136/jitc-2021-002535" target="_blank" rel="noopener">Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis
in this message
